First Ever Double-Blind Human Ingestion Study on Nanosilver
American Biotech Labs has just released what is believed to be the first ever human ingestion safety study on a colloidal silver supplement.
The published abstract for the study states that ingestion of the patented ABL nanosilver particle showed no negative effects on any tested system in the body. The study included 3, 7 and 14-day exposures to American Biotech Labs 10 ppm (15 ml/day) silver solution in a double-blind, placebo-controlled cross-over phase design.
Healthy volunteer subjects (36 subjects in all, 12 per each time-exposure studied), underwent complete metabolic, blood and platelet count, urinalysis tests, sputum hyper-responsiveness and inflammation evaluation, physical examinations, vital sign measurements, and magnetic resonance imaging of the chest and abdomen at baseline and at the end of each phase. According to the study authors, “No clinically important changes in any metabolic, hematologic, or urinalysis measure identified were determined. No morphological (or structural) changes were detected in the lungs, heart (cardiac function) or abdominal organs. No changes were noted in sputum reactive oxygen species or in pro-inflammatory cytokines.”
